H.C. Wainwright Remains a Buy on Disc Medicine (IRON)

Tip Ranks
2025.11.14 23:38
portai
I'm PortAI, I can summarize articles.

H.C. Wainwright analyst Douglas Tsao maintains a Buy rating on Disc Medicine with a price target of $118.00. Tsao, who covers the Healthcare sector, has an average return of 22.0% and a 53.85% success rate. The analyst consensus suggests a Strong Buy rating for Disc Medicine with an average price target of $114.91.

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Disc Medicine today and set a price target of $118.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Hansa Biopharma AB, and Alkermes. According to TipRanks, Tsao has an average return of 22.0% and a 53.85% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $114.91 average price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.